Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Summary

This is an open-label, single-arm, single-center,exploratory clinical study.

Timeline

Start

2026-09-01

Primary completion

2030-09-01

Completion

2031-09-01

Drugs

Indications